Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00500188 · ClinicalTrials.gov registry record · Phase 2
Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT00500188: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00500188 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00500188, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
Primary objectives 1. To determine whether induction of apoptosis or inhibition of angiogenesis are involved in the antitumor activity of (Gleevec, Formerly STI-571) in patients with gastrointestinal stromal tumors (GIST) as assessed by Positron Emission Tomography (PET) scanning. 2. To determine whether dynamic computed tomography (CT), PET scan, molecular and histopathologic responses in GIST tumors from patients treated with Gleevec predict Disease-Free Survival (DFS) time. Secondary objectives 1. To determine the disease free survival of patients with resectable or partially resectable gastrointestinal stromal tumors treated with Gleevec preoperatively and continued for 2 years after resection of disease. 2. To assess the safety and tolerability of Gleevec given to patients with GI stromal tumors 3, 5, or 7 days preoperatively and continued postoperatively.
Interventions
- DRUG Imatinib Mesylate (Gleevec)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2003-07 |
| Est. Completion | 2011-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00500188
The ClinicalTrials.gov registry entry for NCT00500188 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Imatinib Mesylate (Gleevec) is the first listed.
NCT00500188 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00500188 about?
NCT00500188 is a clinical study titled "Preoperative and Postoperative Imatinib Mesylate Study in Patients With c-Kit Positive GIST". Primary objectives 1. To determine whether induction of apoptosis or inhibition of angiogenesis are involved in the antitumor activity of (Gleevec, Formerly STI-571) in patients with gastrointestinal stromal tumors (GIST) as assessed by Positron Emission Tomography (PET) scanning. 2. To determine w...
What is the current status of trial NCT00500188?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2003-07. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00500188?
The interventions under investigation include: Imatinib Mesylate (Gleevec) (DRUG).
Who is sponsoring clinical trial NCT00500188?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.